Tretinoin and hair loss is a topic that raises genuine questions for patients using this prescription retinoid, whether for acne or off-label purposes. Tretinoin is a vitamin A derivative licensed in the UK primarily for acne vulgaris, but its effects on the scalp and hair follicles are less well understood. Whilst systemic retinoids such as isotretinoin are known to cause hair shedding, the evidence for topical tretinoin is far less clear-cut. This article explores what the science and UK regulatory guidance actually say, when to seek medical advice, and how to manage any hair changes safely.

How Tretinoin Affects the Scalp and Hair Follicles

Tretinoin promotes cellular turnover and normalises keratinisation, but its clinical effect on the human hair cycle is poorly characterised and considered theoretical rather than established.

Tretinoin is a topical retinoid derived from vitamin A, used in dermatology primarily for the treatment of acne vulgaris. In the UK, topical tretinoin is licensed for acne — for example, as Treclin gel (clindamycin 1%/tretinoin 0.025%), as listed in the MHRA/EMC Summary of Product Characteristics (SmPC). Use of topical tretinoin for photoageing, pigmentation disorders, or scalp conditions is not a licensed indication in the UK and would be considered off-label; any such use should only occur under specialist supervision.

Tretinoin works by binding to retinoic acid receptors in skin cells, normalising keratinisation, exerting a comedolytic effect, and promoting cellular turnover. These mechanisms make it effective for acne, but they also mean that tretinoin can exert a biological effect on the scalp environment if applied there — including local irritation, increased photosensitivity, and disruption of the skin barrier.

The hair follicle is a complex, cycling structure that passes through phases of growth (anagen), regression (catagen), and rest (telogen). Laboratory research suggests that retinoic acid signalling may play a role in follicular biology, but the clinical relevance of topical tretinoin on the human hair cycle remains poorly characterised and should be regarded as theoretical rather than established. Any changes to hair texture, density, or growth observed during tretinoin use should be considered in the context of the individual's overall health, hormonal status, and concurrent medications, rather than attributed solely to the retinoid itself.

Scalp application of tretinoin for hair loss is off-label and should only be undertaken on the explicit advice of a dermatologist or other specialist clinician.

Not sure if this is normal? Chat with one of our pharmacists →

Is Hair Loss a Recognised Side Effect of Tretinoin?

Alopecia is not listed as a recognised adverse effect of topical tretinoin in its UK SmPC, though scalp irritation from off-label use could theoretically trigger temporary telogen effluvium.

Hair loss (alopecia) is a recognised adverse effect of systemic retinoids such as isotretinoin and acitretin, as documented in their respective MHRA/EMC SmPCs. Both medicines are used in the UK under strict dermatological supervision. However, the picture is less clear for topical tretinoin. The SmPC for Treclin gel — the principal UK-licensed topical tretinoin-containing product — lists local skin reactions (irritation, dryness, peeling, and erythema) as the primary adverse effects; alopecia is not listed as a recognised adverse effect of topical tretinoin.

That said, there are plausible, though not well-evidenced in humans, mechanisms by which topical tretinoin applied to the scalp could contribute to hair shedding in some individuals:

• Scalp irritation and inflammation: Tretinoin can cause significant local irritation. Chronic perifollicular inflammation is a recognised trigger for telogen effluvium — a temporary, diffuse form of hair shedding.

• Potential disruption of the follicular cycle: Some laboratory data suggest retinoids may influence follicular cycling, though this has not been reliably demonstrated in clinical studies with topical tretinoin.

• Barrier disruption: Compromised scalp skin integrity may indirectly affect follicular health over time.

These mechanisms remain theoretical and should not be interpreted as establishing a causal link between standard topical tretinoin use and clinically significant hair loss. Patients who notice increased hair shedding during tretinoin use should report this to their prescriber. Suspected adverse drug reactions can also be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

What the Evidence Says About Tretinoin and Hair Growth

Small older studies suggested tretinoin may improve minoxidil absorption, but evidence is insufficient for NICE or UK dermatological guidelines to recommend tretinoin for hair loss.

The relationship between tretinoin and hair is not exclusively negative. A body of research — predominantly from the 1980s and 1990s — explored whether topical tretinoin could enhance hair regrowth, particularly in androgenetic alopecia (male and female pattern hair loss). Several small studies suggested that tretinoin, when used in combination with minoxidil, may improve the absorption and efficacy of minoxidil by enhancing skin permeability. One frequently cited study published in the Journal of the American Academy of Dermatology examined a combination of tretinoin 0.025% and minoxidil 0.5%; however, it should be noted that 0.5% minoxidil is not a UK-licensed strength — minoxidil is currently licensed in the UK as a 2% or 5% topical solution or foam for androgenetic alopecia.

These studies were generally small, methodologically limited, and have not been replicated in large-scale randomised controlled trials. As a result, tretinoin is not recommended by NICE or endorsed by UK dermatological guidelines as a standalone or adjunctive treatment for hair loss. NICE Clinical Knowledge Summaries (CKS) for androgenetic alopecia identify topical minoxidil and, in appropriate cases, oral finasteride (for men) as the evidence-based pharmacological options in UK primary care.

More recent laboratory research has continued to explore retinoid signalling pathways in hair follicle biology, but translating these findings into clinical practice requires considerably more robust evidence. Patients should be cautious about self-treating hair loss with tretinoin based on anecdotal reports or unregulated online sources, as inappropriate use carries real risks of skin damage and potential worsening of hair shedding.

When to Speak to a GP or Dermatologist

Seek GP or dermatology advice if hair shedding persists beyond 8–12 weeks, if there is visible thinning, patchy loss, or scalp symptoms, or if hair loss accompanies systemic symptoms.

Anyone using tretinoin — whether prescribed for acne or another indication — who notices changes in their hair should seek professional advice rather than self-managing. Whilst mild, temporary shedding can occasionally occur as the skin and scalp adjust to a new topical treatment, persistent or significant hair loss warrants proper clinical evaluation.

You should contact your GP or dermatologist if you notice:

• Increased hair shedding lasting more than 8–12 weeks

• Visible thinning at the crown, temples, or hairline

• Patches of hair loss (which may suggest alopecia areata, an autoimmune condition unrelated to tretinoin)

• Scalp soreness, persistent redness, scaling, or crusting

• Rapidly progressive hair loss or features suggesting scarring alopecia (pain, tenderness, loss of follicular openings), which warrant prompt dermatology referral

• Hair loss accompanied by other symptoms such as fatigue, weight changes, or irregular periods (which may indicate an underlying thyroid or hormonal disorder)

A GP can arrange relevant blood tests to exclude systemic causes before attributing hair changes to tretinoin. Investigations routinely recommended in UK primary care include full blood count (FBC), serum ferritin, and thyroid-stimulating hormone (TSH). Testing for androgens (such as testosterone, sex hormone-binding globulin, and prolactin) is generally reserved for patients with clinical features suggesting hyperandrogenism, such as hirsutism, persistent acne, or irregular menstrual cycles, in line with NICE CKS guidance on androgenetic alopecia and telogen effluvium.

It is also worth reviewing whether any other medications have been started concurrently, as polypharmacy — including systemic retinoids — is a common and underappreciated cause of hair shedding. If tretinoin has been self-purchased online without a prescription, it is particularly important to disclose this to a healthcare professional, as unlicensed or incorrectly formulated products carry additional risks. A dermatologist can assess whether continued use is appropriate and advise on safe application practices.

Managing Hair Changes While Using Tretinoin

Reducing application frequency, using the lowest effective concentration, and optimising scalp care are practical first steps; telogen effluvium typically resolves within three to six months once the trigger is addressed.

If hair changes are suspected to be related to tretinoin use, there are several practical steps that can help manage the situation whilst awaiting professional review. The first consideration is whether tretinoin is being applied to the scalp directly — if so, this should be discussed with the prescribing clinician, as scalp application is not a licensed use in the UK and may be contributing to local irritation.

Practical management strategies include:

• Reducing frequency of application: If tretinoin is being used daily, a prescriber may advise reducing to alternate nights to lower cumulative irritation.

• Using the lowest effective concentration: In the UK, the principal licensed topical tretinoin product (Treclin gel) contains tretinoin 0.025%. Other concentrations may be available as unlicensed specials; patients should only use concentrations prescribed or recommended by their clinician.

• Optimising scalp care: Using a gentle, sulphate-free shampoo and avoiding excessive heat styling can reduce additional mechanical stress on hair follicles during a period of potential shedding.

• Sun protection: Tretinoin increases photosensitivity; applying sunscreen to exposed areas and avoiding prolonged sun exposure is important.

• Addressing iron deficiency: Iron deficiency is a common and correctable contributor to hair shedding. If serum ferritin is low, dietary improvement or supplementation under clinical guidance is appropriate. Vitamin D should be assessed and supplemented according to clinical risk and local guidance.

• Zinc and biotin: Routine zinc or biotin supplementation is not recommended for hair loss in the absence of confirmed deficiency. Biotin (vitamin B7) supplements can interfere with a range of laboratory tests, including thyroid function tests and troponin assays, potentially producing misleading results — as highlighted in an MHRA Drug Safety Update. Patients should inform their clinician if they are taking biotin supplements before blood tests are arranged.

• Pregnancy and breastfeeding: Topical retinoids, including tretinoin, are contraindicated in pregnancy per the SmPC. Patients who are pregnant, planning a pregnancy, or breastfeeding should stop topical tretinoin and seek advice from their clinician promptly.

• Avoiding abrupt discontinuation without advice: Stopping tretinoin suddenly without guidance may not be necessary and could disrupt an otherwise effective treatment regimen.

Telogen effluvium — if that is the underlying cause — is typically self-limiting and resolves within three to six months once the triggering factor is addressed, as outlined in NICE CKS guidance on telogen effluvium. Reassurance and monitoring are often the most appropriate initial approach, alongside a thorough clinical assessment.

MHRA and NICE Guidance on Tretinoin Use in the UK

Tretinoin is a UK prescription-only medicine licensed for acne only; NICE does not recommend it for hair loss, and suspected adverse reactions should be reported via the MHRA Yellow Card Scheme.

Experiencing these side effects? Our pharmacists can help you navigate them →

In the UK, tretinoin is a prescription-only medicine (POM) regulated by the MHRA. Topical tretinoin is licensed for the treatment of acne vulgaris; the principal licensed product is Treclin gel (clindamycin 1%/tretinoin 0.025%), as detailed in its MHRA/EMC SmPC. Topical tretinoin is not licensed in the UK for photoageing, pigmentation disorders, or hair loss; any use for these purposes is off-label and should only occur under appropriate specialist supervision. Patients should be aware that private clinics or online providers offering tretinoin for photoageing or hair loss are doing so outside the licensed indication.

NICE guidance on acne vulgaris (NG198, published 2021) recommends topical retinoids, including tretinoin, as part of combination therapy for mild-to-moderate acne. NICE does not currently recommend tretinoin for the treatment of hair loss. NICE Clinical Knowledge Summaries (CKS) for androgenetic alopecia and telogen effluvium direct clinicians and patients towards evidence-based options: topical minoxidil (2% or 5%) and, in appropriate cases, oral finasteride (for men) are the pharmacological treatments supported by UK guidance for androgenetic alopecia.

The European Medicines Agency (EMA) similarly does not list hair loss as an indication for topical tretinoin. Systemic retinoids — isotretinoin and acitretin — carry a well-established association with alopecia as an adverse effect (documented in their respective SmPCs) and are subject to the Pregnancy Prevention Programme (PPP) in the UK due to their teratogenic risk. The PPP is overseen by the MHRA and applies to oral isotretinoin and acitretin. Whilst topical tretinoin is not subject to the PPP, it is nonetheless contraindicated in pregnancy per its SmPC; patients should use effective contraception during treatment and stop immediately if they become pregnant or are planning a pregnancy.

Patients are advised to source tretinoin only through registered UK pharmacies or NHS prescriptions. Unregulated online suppliers offering unlicensed formulations may provide products with inaccurate concentrations and pose additional safety risks. Suspected adverse reactions to any tretinoin-containing product should be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Frequently Asked Questions